

THE ONLY WAY IS UP...

PHARMA & BIOTECH AT THE END OF Q2

M&A

Is the famine over? M&A is finally back on the menu



Q1

Q2



\$12 BN

VALUE



\$25 BN

42

34



IPO

The worst quarter in a decade for IPOs



Q1

Q2



8
OF THE 13 ARE ALREADY
TRADING UNDER WATER



VENTURE FUNDING

Industry malaise hits private companies too...

VC ROUNDS


Q1

Q2

133
\$9 BN

82
\$4 BN

Q2 2022 BIOPHARMA Breakdown by Value




H1 SHARE PRICE PERFORMANCE

Even safe havens are looking less appealing


▲ GOING UP

+23% **+28%** **+31%** **+129%**



▼ GOING DOWN

-16% **-44%** **-70%** **-95%**



*of the 660 tracked by Evaluate Vantage